Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Vivani Medical Inc. - news published 181 - readings 2.192

BACK

Vivani Medical Inc.

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSIO ...

01.04.2025

Vivani Medical Inc.

Annual Report for Fiscal Year Ending 12-31, 2024 (Form 10-K)

Item 7 . Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. The consolidated results of operations for the years e ...

31.03.2025

Vivani Medical Inc.

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (Form 8-K)

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 (semaglutide implant) preclinical weight loss data comparable ...

31.03.2025

Vivani Medical Inc.

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results March 31, 2025 7:30am EDT Download as PDF Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 (semaglutide implan ...

31.03.2025

Vivani Medical Inc.

Vivani Medical Announces $8.25M Private Placement Equity Financing (Form 8-K)

Vivani Medical Announces $8.25M Private Placement Equity Financing Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management Alameda, CA -- (GLOBE NEWSWIRE) - March 26, 2025 - Vivani Medical, ...

27.03.2025

Vivani Medical Inc.

Vivani Medical Announces $8.25M Private Placement Equity Financing

Vivani Medical Announces $8.25M Private Placement Equity Financing March 27, 2025 7:32am EDT Download as PDF Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 2 ...

27.03.2025

Vivani Medical Inc.

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM 139 Semaglutide Implant, with Potential for Once Yearly Dosing

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing March 26, 2025 7:30am EDT Download as PDF NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20% ...

26.03.2025

Vivani Medical Inc.

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing (Form 8-K)

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing NanoPortalTM technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single ...

26.03.2025

Vivani Medical Inc.

Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business (Form 8-K)

Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent shareholders Cortigent's Orion® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging safety and efficacy results Formerly Second S ...

13.03.2025

Vivani Medical Inc.

Vivani Medical Achieves First Implant and Full Enrollment in the First in Human Clinical Trial of GLP 1 Implant NPM 115 in Obese or Overweight Adults

Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults March 13, 2025 7:30am EDT Download as PDF Miniature, twice-yearly GLP-1 (exenatide) implant under development for chronic weight management NPM-115 has demonstrated comparable preclinical weight loss to injections of semaglutide, ...

13.03.2025

Vivani Medical Inc.

Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business

Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business March 12, 2025 8:30am EDT Download as PDF Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent shareholders Cortigent's Orion ® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging sa ...

12.03.2025

Vivani Medical Inc.

Statement of Changes in Beneficial Ownership (Form 4)

04.03.2025

Vivani Medical Inc.

2025 Investor Presentation

Nasdaq: VANI www.vivani.com Vivani Medical, Inc. Guaranteed Adherence. Better Outcomes. January 2025 Vivani Executive Leadership Team Adam Mendelsohn PhD - CEO/Director Co-founder/Co-inventor of Vivani technology PhD Bioengineering (UCSF/UC Berkeley) Management of Technology Certificate at Haas School of Business Research focused on diabetes treatment Formerly at Boston Scient ...

14.01.2025

Vivani Medical Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Ownership Submission FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES A ...

04.01.2025

Vivani Medical Inc.

Statement of Changes in Beneficial Ownership (Form 4)

04.01.2025

Vivani Medical Inc. - news published 181 - readings 2.192

Vivani Medical Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Vivani Medical Inc.

Annual Report for Fiscal Year Ending 12-31, 2024 (Form 10-K)

Vivani Medical Inc.

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (Form 8-K)

Vivani Medical Inc.

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vivani Medical Inc.

Vivani Medical Announces $8.25M Private Placement Equity Financing (Form 8-K)

Vivani Medical Inc.

Vivani Medical Announces $8.25M Private Placement Equity Financing

Vivani Medical Inc.

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM 139 Semaglutide Implant, with Potential for Once Yearly Dosing

Vivani Medical Inc.

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing (Form 8-K)

Vivani Medical Inc.

Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business (Form 8-K)

Vivani Medical Inc.

Vivani Medical Achieves First Implant and Full Enrollment in the First in Human Clinical Trial of GLP 1 Implant NPM 115 in Obese or Overweight Adults

Vivani Medical Inc.

Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business

Vivani Medical Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Vivani Medical Inc.

2025 Investor Presentation

Vivani Medical Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Vivani Medical Inc.

Statement of Changes in Beneficial Ownership (Form 4)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member